Using Stz Diabetic Rats ( Vanadium ) - 1844 Words

Abstract Vanadium complexes have been synthesized, characterized, and tested as possible insulin-enhancing agents using STZ-diabetic rats. The vanadyl complexes, bis(maltolato)oxovanadium(IV), BMOV, bis(ethylmaltolato)oxovanadium(IV), BEOV, and bis(isopropylmaltolato)oxovanadium(IV), BIOV, were compared for glucose-decreasing capability against vanadyl sulfate, when administered to the rats at a one-time dose of 0.1 mmol kg–1 body weight. After the injection, blood levels of vanadium were recorded at regular intervals for 72 hours. When compared to vanadyl sulfate, all complexes exceeded in glucose-lowering ability. This was not correlated with blood vanadium levels. Pharmokinetics indicates that the metal ion-ligand dissociation took place quickly after oral ingestion of the complex. Other comparable synthetic methods also using an oral hypoglycemic agent, commonly known as metformin, complexed with vanadium(IV) to form vanadyl metformin [VO(metf)2].1 Introduction Diabetes mellitus is a category of metabolic diseases distinguished by hyperglycemia from defects in insulin secretion, insulin action, or both. The most widespread form of this disease is Type 2 diabetes mellitus (T2DM) which accounts for 85-95% of all diagnosed cases. Often times these cases are without symptoms during their early stages and sometimes remains undetected for many years. The chronic hyperglycemia of diabetes is connected with enduring dysfunction and damage to various organs including the eyes,